Abstract 396P
Background
Despite the many cervical cancer prevention interventions recommended and supported by WHO and partners of low- and middle-income countries; the burden of cancer is high in Uganda and the East African region. Little is known about factors associated with participating in screening at a primary health facility (PHF) and referral to a high-level facility.
Methods
A cross-sectional study was conducted from February to March 2018 at Uganda Cancer Institute (UCI) among women visiting for cervical cancer screening. A structured questionnaire was used. Women suspected for cervical cancer and provided consent were enrolled and administered the questionnaire. Ethics review and approval was obtained from UCI research and ethics committee. A Stata version 14.1 software was used and Chi-square tests and multivariate logistic regression analyses performed.
Results
Among 522 women enrolled, only 3.26% (17) had a formal referral note and 62.64% (327) had participated in cervical cancer screening before visiting UCI. There was a 17.65% false-positive rate among the referred women suspected with cervical cancer. 67.18% (131) among those who had never screened reported personal beliefs as a factor deterring their participation. Most women were aged between 35-44 years old (ORs=2.45, 95% CI = 1.61-3.72) who were divorced/widowed (ORs=1.89, 95% CI = 1.07-3.34) and drinking alcohol (ORs=0.51, 95% CI = 0.31-0.83). Among the referred women, 17.65% delayed to honour a referral request for more than a month because of socio-economic challenges. Factors such as high education level (ORs=0.11, 95% CI = 0.02-0.48) and confirmatory tests (ORs=6.10, 95% CI = 1.93-19.31) done at UCI were associated with referrals.
Conclusions
The present study identified factors associated with participation in screening at a PHF and referral to a high-level facility, which provides better understanding of lost follow-up after screening. Awareness in high risk groups, increase of screening facilities and integration of screening services with existing health programs is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Uganda Cancer Institute-African Development Bank capacity building fund.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract